Investigational drug · Phase 3
XNW28012
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pancreatic Cancer, Advanced Solid Tumors, Pancreatic Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "XNW28012"
First trial start
2023
Dec 1, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "XNW28012", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pancreatic Cancer
- Advanced Solid Tumors
- Pancreatic Carcinoma
- Ovarian Cancer
- Cervical Cancers
Approved drugs for the same conditions: Ovarian cancer · Pancreatic cancer · Cervical cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "XNW28012" as an intervention, largest first.
Evopoint Biosciences Inc.Industry
NCT06799637 · 350 participants (planned) · Start Dec 1, 2023 · Primary completion Dec 31, 2026
Drug: XNW28012 · For: Advanced Solid Tumors; Pancreatic Carcinoma; Ovarian Cancer and 1 more
Sites: Hefei, China; Beijing, China; Chongqing, China · 24 sites in all
- Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic TherapyPivotal-lookingRecruiting
Evopoint Biosciences Inc.Industry
NCT07823049 · 226 participants (planned) · Start Jul 8, 2025 · Primary completion May 31, 2027
Drug: XNW28012 for injection; XNW28012 Mimetic for Injection · For: Pancreatic Cancer
Sites: Shanghai, China; Beijing, China; Binzhou, China · 48 sites in all
- Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic CancerNot yet recruiting
Evopoint Biosciences Inc.Industry
NCT07707674 · 24 participants (planned) · Start Jul 30, 2026 · Primary completion Apr 30, 2028
Drug: XNW28012 · For: Metastatic Pancreatic Cancer
Sites: Detroit, Michigan; Grand Rapids, Michigan; Lake Success, New York · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Pancreatic Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- GEMPhase 35 trials
Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer
- HRS-7058Phase 35 trials
Shandong Suncadia Medicine Co., Ltd. · KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment, Solid Tumors, Pancreatic Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.